ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MIRM vs MANE // EV/EBITDA & P/E VALUATION

Mirum Pharmaceuticals Inc. (NASDAQ) VS. Veradermics Incorporated (NYSE) • 15-METRIC TALLY: MIRM 5 — MANE 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIRM VS. MANE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MIRM MANE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -3.90% -11.90% +8.00 MIRM /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield 0.98% -1.19% +2.17 MIRM /fcf-yield <GO>
Operating Margin -4.20% -4.30% +0.10 MIRM /operating-margins <GO>
Net Profit Margin -4.50% -4.20% -0.30 MANE /net-margins <GO>
Revenue Growth (YoY) 54.70% 4.40% +50.30 MIRM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.29 26.00 -19.71 MANE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 4/9 +4.00 MIRM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.4 60.4 -12.00 MANE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.99 1.07 -0.08 MANE /macro-sensitivity <GO>
Forward P/E Multiple 32.0x 24.0x +8.00 MANE /forward-pe <GO>
Enterprise Scale & Market Cap $5.52B $5.84B -$317.0M MANE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MIRM REV MANE REV MIRM GROSS % MANE GROSS % MIRM FCF MANE FCF
FY 2025 $521.3M $202.6M — — $54.9M -$71.6M
FY 2024 $336.9M $75.0M — — $9.3M -$23.7M
FY 2023 $186.4M — — — -$79.3M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIRM // BETA 0.99
MANE // BETA 1.07